| Date | Time | Source | Headline | Symbol | Company |
| 05/02/2024 | 2:07PM | iHub Newswire | FeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon | | |
| 04/30/2019 | 7:00AM | GlobeNewswire Inc. | ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/12/2019 | 4:01PM | GlobeNewswire Inc. | Harrow Health Announces Fourth Quarter 2018 Financial Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/04/2019 | 7:00AM | GlobeNewswire Inc. | Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 02/28/2019 | 7:00AM | GlobeNewswire Inc. | Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 02/13/2019 | 7:00AM | GlobeNewswire Inc. | Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 02/07/2019 | 7:00AM | GlobeNewswire Inc. | Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 02/05/2019 | 7:00AM | GlobeNewswire Inc. | Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 01/03/2019 | 5:27PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 12/31/2018 | 7:01AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 12/31/2018 | 7:00AM | GlobeNewswire Inc. | Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc. | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 12/17/2018 | 6:29AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 12/06/2018 | 6:12AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/16/2018 | 7:30AM | GlobeNewswire Inc. | Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™ | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/13/2018 | 4:23PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/13/2018 | 4:22PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/13/2018 | 4:01PM | GlobeNewswire Inc. | Imprimis Pharmaceuticals Announces Third Quarter 2018 Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/13/2018 | 12:01PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/06/2018 | 7:16AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/06/2018 | 7:00AM | GlobeNewswire Inc. | Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 11/02/2018 | 6:21PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 10/29/2018 | 6:13AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 10/23/2018 | 7:00AM | GlobeNewswire Inc. | Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioi... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 10/18/2018 | 9:11AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 10/16/2018 | 7:00AM | GlobeNewswire Inc. | ImprimisRx to feature new formulation and poster presentation on MKO Melt® at the upcoming American Academy of Ophthalmology... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 09/07/2018 | 5:33PM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 09/05/2018 | 7:46PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 08/15/2018 | 7:01AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 08/13/2018 | 6:16AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 08/08/2018 | 7:05AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |